Novartis India Q1 FY27 results: Revenue up 18.6% YoY, PAT at Rs 322.1 mn

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.9%1-day move

₹1699.80

prior close

₹1645.90

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+2.6+0.4+2.8+2.0-2.9-4.2-6.9———————

Up moveDown movePending

AI summary

Board approved unaudited Q1 FY27 results for the quarter ended June 30, 2026. Revenue from operations rose 18.6% YoY to Rs 1,038.1 mn versus Rs 875.5 mn in Q1 FY26. Total income at Rs 1,125.5 mn. Profit before tax up 16% to Rs 431.7 mn. Net profit at Rs 322.1 mn versus Rs 276.2 mn. EPS at Rs 13.05 versus Rs 11.19. Limited review report by BSR and Co LLP was clean with no qualifications. Note 6 flags the ongoing change of control: parent Novartis AG has signed an SPA to sell its 70.68% stake to WaveRise, ChrysCapital and TwoInfinity Partners, awaiting completion.

Likely market impact

Healthy quarter with double digit revenue and profit growth. Major overhang remains the pending 70.68% stake sale by parent Novartis AG.